GlassScriptPhysician profile
Jeremy D Brown
NPI 1760861116
$2,791.54
in general payments reported to CMS, 2019-2025
32 companies · $188 in 2025
The $188 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $636 · 2020: $368 · 2021: $485 · 2022: $574 · 2023: $251 · 2024: $290 · 2025: $188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $644 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $643.68 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $509.97 | 2019-2025 | Ubrelvy |
| Glaxosmithkline, LLC. | $314.28 | 2019-2024 | Arexvy, Shingrix |
| Novo Nordisk INC | $303.82 | 2019-2023 | Ozempic, Tresiba, Rybelsus |
| Eisai INC. | $203.44 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $177.89 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $169.00 | 2022 | |
| Merck Sharp & Dohme LLC | $154.62 | 2019-2024 | Capvaxive, Vaqta, Gardasil 9 |
| Gilead Sciences, INC. | $115.85 | 2019 | |
| Lilly USA, LLC | $105.62 | 2019-2023 | Emgality, Jardiance, Mounjaro |
| Janssen Pharmaceuticals, INC | $93.84 | 2019-2021 | |
| Astellas Pharma US INC | $84.99 | 2025 | |
| Exact Sciences Corporation | $80.93 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $52.92 | 2021-2025 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.47 | 2019 | |
| Intersect Ent, INC. | $39.46 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $34.14 | 2022 | |
| Integra Lifesciences Corporation | $33.32 | 2024 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Bayer Healthcare Pharmaceuticals INC. | $32.27 | 2023 | |
| Amarin Pharma, INC. | $24.74 | 2021 | |
| Genentech USA, INC. | $23.66 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.64 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $23.50 | 2019 | |
| Idorsia Pharmaceuticals US INC | $22.61 | 2024 | Quviviq |
| Pfizer INC. | $18.57 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $14.41 | 2019 | |
| Sun Pharmaceutical Industries INC. | $14.34 | 2021 | |
| Sanofi Pasteur INC. | $13.90 | 2019 | |
| Currax Pharmaceuticals LLC | $13.10 | 2021 | |
| Abbott Laboratories | $13.00 | 2019 | |
| Adlon Therapeutics L.P. | $12.35 | 2019 | |
| Shire North American Group INC | $12.30 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeremy Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.